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Predictive chemosensitivity testing in malignant melanoma: Reliable
methodology - ineffective drugs
K.M. Tveit, S. Gundersen, J. Hoie & A. Pihl
The Norwegian Radium Hospital and Institute for Cancer Research, Montebello, 0310 Oslo 3, Norway
Summary A retrospective and a prospective trial were carried out in patients with malignant melanomas to
investigate the predictive value of an in vitro chemosensitivity assay based on the Courtenay and Mills soft
agar cultivation method. Evaluable in vitro chemosensitivity data for the three agents DTIC, CCNU, and
vinblastine were obtained in 153 cases. In the retrospective study in which the patients received chemotherapy
without prior knowledge of the test results, 50 in vitro/in vivo correlations (40 patients) were made, and in the
prospective study, where patients received the single agent most active in vitro, 55 correlations (45 patients)
were performed. In both studies the sensitivity of the test (the ability to identify patients who will respond to
chemotherapy) was 100% and the specificity (the ability to identify patients who will not respond) was 87-
98%. Depending on whether 'no change' and 'mixed response' were classified as sensitivity or resistance, the
predictive value of a negative test was - 100% and that of a positive test 37.5-87.5%. The response rate was
low in both series, and although it was somewhat higher in the prospective than in the retrospective trial, the
difference was not significant. The median survival time was not significantly different in the two treatment
series. We conclude that the chemosensitivity assay here used is reliable and has predictive value, but that the
chemotherapeutic agents currently available for treatment of melanoma are too ineffective to -warrant routine
use of the assay in this disease.
During the last decade, starting with the pioneer work of
Salmon et al., (1978), a large number of laboratories have
attempted to use chemosensitivity testing in vitro, based on
semi-solid medium, as a guide to the treatment of various
human malignant tumours. Several interesting reports on the
predictive value of such tests in various human tumours have
appeared. Although the initial enthusiasm for predictive
testing has declined, such testing may be useful in certain
types of cancer (Alberts et al., 1984; Welander et al., 1984;
Hanauske et al., 1985) and the prediction concept has
prompted valuable basic and clinically relevant studies of cell
biology and therapy responses in vitro.
Malignant melanomas lend themselves to chemosensitivity
testing insofar as they are rather easy to grow in semi-solid
medium, and several reports on predictive chemosensitivity
testing in this tumour type have appeared. Positive cor-
relations between in vitro sensitivity and clinical response
have been reported, but a beneficial value of the test systems
in the routine chemotherapy of patients has not been
established (Meyskens et al., 1981, 1984; Bertelsen et al.,
1984; Mackie et al., 1984; Tveit et al., 1982, 1985). Here we
report on our experience in a retrospective and prospective
trial of malignant melanoma using a cultivation method
different from that used by most workers, and also a
different calibration method of the in vitro results.
Materials and methods
Tumours
Altogether 402 histologically verified malignant melanomas
(metastases or local recurrences), surgically removed from
patients admitted to The Norwegian Radium Hospital, were
disaggregated by a mechanical procedure employing a
stomacher (Tveit et al., 1984). The cell suspension was
filtered through a 45 iM nylon mesh, washed and
resuspended in Hams F12 medium supplemented with 15%
foetal calf serum, 100IUml-1 penicillin and 100pgml-1
streptomycin. The yield of tumour cells was calculated, and
in the cases where a high enough yield was obtained to
permit chemosensitivity studies, chemosensitivity experiments
were performed. The viability of disaggregated tumour cells,
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as determined in the phase contrast microscope by scoring
intact cells with a bright outline as viable, was in the range
40-80%.
Chemosensitivity assay
In 240 cases, chemosensitivity experiments, including at least
three anti-cancer agents, were performed. Cells (5 x 105) were
treated with 4 different concentrations of dacarbazine
(DTIC, 80, 250, 800 and 2,500jigml-1), lomustine (CCNU,
0.04, 0.4, 4 and 40 jgml-1) and vinblastine (VBL) (0.01, 0.1,
1 and 10 igml-1) for 1 h during continuous agitation. In
addition, a positive control with abrin (10jigml -) was
included. The anti-cancer agents were dissolved in PBS
(DTIC, vinblastine and abrin) or cremophor EL (CCNU) and
were stored in aliquots at -70°C. DTIC was protected from
light both during storage and the experimental procedure.
After incubation, the cells were washed twice in PBS and
resuspended in complete medium. The number of viable cells
was scored, and the soft agar cultures were set up in
triplicate.
The soft agar method described by Courtenay and Mills
(1978) was used (Tveit et al., 1984). Briefly, cultures of
treated and untreated cells were set up in culture tubes by
adding 0.2ml of a suspension of washed and heated rat
erythrocytes diluted 1:8, 0.2ml of the tumour cell suspension
(properly diluted to give 2 x 104 viable cells in each culture)
and 0.6ml 0.5% agar. After mixing the components and
solidification of the agar, the tubes were placed with the caps
in the open position in an incubator controlling the exact
concentrations of 02 (5%), CO2 (5%) and N2 (90%). On
the next day the tubes were sealed, and after - 7 days 1 ml
medium was added to each tube. Counting of colonies was
usually performed after 2 weeks (alternatively 3 weeks),
using a stereo microscope. Colonies of more than 30 cells, or
with a diameter of a least 100,jm were scored. Only
experiments with abrin negative controls were included in the
study. To evaluate chemosensitivity, at least 30 colonies in
the controls were required.
Clinical treatment
In the retrospective trial the patients received single-agent
DTIC, CCNU or vinblastine treatment, chosen by the
clinician without prior knowledge of the in vitro test results
on tumour specimens. In the prospective study the clinician
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waited for the in vitro testing and treated the patient with
the one of the three agents that was most active in vitro (see
below). In both studies, DTIC was used at a dosage of
800mgm-2, given every 4 weeks, CCNU at a dosage of
120mgm-2 given every 6 weeks, and vinblastine at
6mgm-2 given every week. Response evaluation was
performed after 2 to 3 months by simple measurements of
palpable lesions, chest X-rays or CT-scans.
Clinical responses were classified according to inter-
national criteria as complete response (CR), partial response
(PR) and progressive disease (PD). In addition, mixed
response (MR) was defined as more than 50% regression of
one or more metastases, while concurrently one or more
lesions increased in size or a new one appeared during
treatment. No change (NC) was defined as lack of pro-
gression of any tumour manifestation for at least 3 months
after prior progression.
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Figure 1 Dose-response relationships for 10 melanomas treated
in vitro with 4 concentrations (see Materials and methods) of
DTIC, CCNU and vinblastine. Two of the DTIC curves are
almost identical and cannot be separated in the graph.
Data analysis
The in vitro chemosensitivity was quantitated on the basis
of the observed dose-response curves. The ID50s (doses
required to inhibit colony formation by 50%) were derived
from the dose-response curves and correlated with the in vivo
sensitivity of melanoma xenografts previously measured
(Tveit et al., 1980, 1982). By this calibration procedure the in
vitro chemosensitivity is converted to an in vivo sensitivity
and is expressed in terms of expected growth delay (EGD).
In our earlier studies (Tveit, 1983), we found that an EGD
limit of 2.0 was a useful cut-off value for predicting tumours
as being either 'sensitive' or 'resistant' in vivo.
'Sensitivity' of the test system was defined as the ability of
the assay to identify patients who will respond to
chemotherapy and 'specificity' as its ability to identify
patients who will not respond to chemotherapy. These
parameters were expressed as follows:
Sensitivity =sS/(sS+rS), and specificity =rR/(rR+sR),
where s and S denote sensitivities in vitro and in the clinic,
respectively, and r and R resistance in vitro and in the clinic,
respectively. Moreover, the 'predictive value of a positive
test' (PV+) was defined as sS/(sS+sR) and the 'predictive
value of a negative test' as rR/(rR+rS).
Results
Altogether 402 malignant melanomas were cultivated in soft
agar and gave evaluable colony formation in vitro. Two
hundred and eighty-five tumours (71%) formed more than
10 colonies and the colony forming efficiencies obtained
ranged from 0.15% up to 20%. Sensitivity testing for DTIC,
CCNU and vinblastine was performed in 240 cases, and in
153 cases of these (64%), evaluable chemosensitivity data
were obtained for all 3 drugs. In 85 patients, 105 correlations
between in vitro data and evaluable clinical responses were
made.
Figure 1 shows representative dose-response relationships
for 10 tumours treated in vitro with DTIC, CCNU and
vinblastine. It is gratifying that none of the dose-response
curves had plateaus. The ID50s were derived graphically and
converted to EGD values as described in the Materials and
methods section and in Tveit et al., (1980). In general, the
same chemosensitivity patterns were found in metastases
compared to local recurrences.
In the retrospective study, 3 partial responses were
observed and in addition 4 patients had no change or mixed
response. In 43 cases progressive disease was found. In the
prospective study, one patient had complete response, 8 had
partial response, 6 had no change or mixed response and 40
had progressive disease.
Figure 2 shows correlations between the estimated EGD
values and the various categories of clinical responses in the
retrospective study (50 cases) and in the prospective study
(55 cases). Table I summarizes the results. In the retro-
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Figure 2 Correlations between in vitro sensitivity (expected
growth delay) and clinical responses (CR, PR, MR, NC, PD, see
text) in 50 cases, retrospective study (open circles) and 55 cases,
prospective study (closed circles).
Table I Correlations between in vitro sensitivity and clinical
response to either DTIC, CCNU or vinblastine in malignant
melanomas
Clinical response
Number.o%f Type of study CR+PR MR+NC PD corretato
Retrospective
In vitro sensitivitya 3 4 1
In vitro resistanceb 0 0 42 50
Prospective
In vitro sensitivitya 9 3 3
In vitro resistanceb 0 3 37
aExpected growth delay (EGD) >2.0; bExpected growth delay
(EGD) <2.0.
spective study, three patients with partial responses all had
tumours that were sensitive in vitro (EGD<2.0), and of 43
cases with progressive disease, 42 had tumours that were
resistant in vitro (EGD> =2.0), whereas one had a sensitive
tumour. Four cases with mixed responses or no change had
sensitive tumours in vitro. In the prospective study, 9
patients with partial or complete responses had sensitive
tumours in vitro. Of 40 cases with progressive disease, 37 had
resistant tumours in vitro, whereas 3 had sensitive tumours in
vitro. Three patients with MR or NC had sensitive tumours
in vitro, whereas 3 other patients had resistant tumours in
vitro.
The estimation of the 'sensitivity' and 'specificity' of the
test and the 'predictive value' of a positive or a negative test
was dependent on whether a mixed response and no change
were classified as clinically sensitive or as clinically resistant
735
c
n n 3.0
. *-
O 0 0736 K.M. TVEIT et al.
(Table II). If MR and NC are classified as clinical resistance,
in the retrospective study the sensitivity was 100%, the
specificity 89%, the predictive value of a positive test (PV+)
was 38%, and the predictive value of a negative test (PV-)
100%. If, however, MR and NC are classified as clinical
sensitivity, the specificity and PV+ values increase (Table II).
In the prospective study, the sensitivity and PV- were 100%
if MR and NC are classified as resistance. The specificity
was 87% and PV+ was 60%. If MR+NC are classified as
sensitive, the consequence is that the sensitivity and PV-
values decrease, and the specificity and PV+ values increase.
In the prospective study, it turned out that DTIC was most
active in 32, CCNU in 14, and vinblastine in 9 of the 55
cases. These findings parallel closely the clinical experience
that DTIC is the most active agent in melanomas, more
active than CCNU and vinblastine. The results show that
relatively more objective clinical responses were obtained in
the prospective than in the retrospective study. Thus,
PR+CR increased from 6.0% in the retrospective study to
16.4% in the prospective study (not statistically significant,
P=0.09, Chi-square test), and NC+MR increased from
8.0% to 10.8%. Altogether, 27.2% of the patients in the
prospective study had some kind of response, compared to
14.0% in the retrospective study (P=0.09).
The median survival was not significantly different in the
two trials (7.3 months in the retrospective and 9.1 months in
the prospective trial).
Discussion
Several significant facts emerge from the present study. In
the first place, the association between in vitro sensitivity and
clinical response was highly significant. This shows that the
assay here used, which is based on the Courtenay and Mills
culture method and calibrated by means of melanoma
Table II Sensitivity, specificity and predictive value of a positive
(PV+) or a negative (PV-) test in malignant melanoma, when
MR+NC is classified as either clinical resistance (R) or as sensitivity
(S)
MR+NC=R MR+NC=S
Retrospective study
Sensitivitya 3/3 = 100% - 7/7 = 100%
Specificityb 42/47 = 89% 42/43 = 98%
PV+c 3/8 = 38% 7/8= 88%
PV_d 42/42=100% 42/42 = 100%
Prospective study
Sensitivitya 9/9 = 100% 12/15 = 80%
Specificityb 40/46= 87% 37/40 = 93%
PV+C 9/15= 60% 12/15= 80%
PV_d 40/40 =100% 37/40 = 93%
asS/(sS+rS); brR/(rR+sR); CsS/(sS+sR); drR(rR+rS).
xenografts, is reliable and has high predictive value.
Secondly, the response rate to the agents tested, considered
by most workers to be among the most efficacious ones in
melanoma, was very low. Although the response rate was
higher in the prospective than in the retrospective study, the
difference was not statistically significant, and the median
survival was not significantly higher in the prospective trial.
Thus, our study fails to demonstrate a definite therapeutic
value of predictive testing in malignant melanoma.
A serious shortcoming of in vitro chemosensitivity testing
is the low percentage of evaluable tests (von Hoff et al.,
1981). In 240 of the 402 specimens received in the
laboratory, a sufficient number of cells was obtained to set
up a test with the 3 different agents at 4 different
concentr.ations. Sixty-four per cent of these experiments
could be evaluated for chemosensitivity to all agents. This
implies that in the majority (62%) of the malignant
melanoma specimens received, chemosensitivity data could
not be obtained, either due to an insufficient number of cells
in the specimen, or to inadequate growth. We do not believe
that these figures can be significantly improved as we have
made considerable efforts to optimize both the dis-
aggregation and the cultivation procedures (Tveit et al.,
1984).
Although the probability of finding a drug capable of
inducing a response undoubtedly will increase with
increasing number of drugs tested, as shown by Meyskens et
al. (1981), such extended testing will be possible only in a
minority of cases, and we doubt that the increase in effort
and expense required will be justified by the results. Thus, in
several cases we have performed testing with 6 different
agents without finding any of them active (not shown), and
we believe that many cases of malignant melanomas may be
resistant to all agents currently available.
In spite of the low response rate of melanoma to current
chemotherapy, many centres continue to administer chemo-
therapy routinely to melanoma patients with metastatic
disease. A rationale for using a predictive assay in a tumour
type such as malignant melanoma, could be to identify the
few tumours that are sensitive and to avoid chemotherapy in
the majority of patients who have unresponsive tumours.
However, in view of the marginal effect of all available
chemotherapy regimens with only minor or partial responses
of short duration without any prolongation of survival time,
we conclude that a routine testing of patients with malignant
melanomas is not justified at the present time. This situation
may change if more active agents become available.
Presently, melanoma patients should, in our opinion, not
have chemotherapy with any of the current cytotoxic agents,
but should preferably be included in clinical Phase II
protocols of promising new agents.
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